Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...
The combination of islatravir and lenacapavir targets multiple stages of HIV-1 replication, potentially offering people with ...
Gilead & Merck announce positive topline results from two phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment: Foster City, California Wednesday, ...
Daily Maverick on MSN
The evolution of HIV treatment: From multi-pill regimens to better, single-pill combos
HIV treatment has been improved and simplified significantly over the years, yet a small fraction of people living with HIV ...
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung ...
Gilead and Merck announce positive phase 3 results for once-weekly oral islatravir/lenacapavir, demonstrating noninferiority in virologically suppressed HIV.
Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
New medicines are getting better. But so is our ability to get them where they need to go.
By Offering Amplicon and Hybrid Capture on a Single Bioinformatics platform, the Company Expands Capabilities to Cover ...
THIS SPRING, Munich, Germany, hosted the 36th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results